Abstract Cancer cells are distinguished by several distinct characteristics, such as self-sufficiency in growth signal, resistance to growth inhibition, limitless replicative potential, evasion of apoptosis, sustained angiogenesis, and tissue invasion and metastasis. Tumor cells acquire these properties due to the dysregulation of multiple genes and associated cell signaling pathways, most of which are linked to inflammation. For that reason, rationally designed drugs that target a single gene product are unlikely to be of use in preventing or treating cancer. Moreover, targeted drugs can cause serious and even life-threatening side effects. Therefore, there is an urgent need for safe and effective promiscuous (multitargeted) drugs. ''Mother Nature'' produces numerous such compounds that regulate multiple cell signaling pathways, are cost effective, exhibit low toxicity, and are readily available. One among these is tocotrienol, a member of the vitamin E family, which has exhibited anticancer properties. This review summarizes data from in vitro and in vivo studies of the effects of tocotrienol on nuclear factor-jB, signal transducer and activator of transcription (STAT) 3, death receptors, apoptosis, nuclear factor (erythroid-derived 2)-like 2 (Nrf2), hypoxia-inducible factor (HIF) 1, growth factor receptor kinases, and angiogenic pathways.
Introduction
Vitamin E, which exhibits antioxidant properties, is a generic term that represents derivatives of tocopherol and tocotrienol (Kamal-Eldin and Appelqvist 1996) . Antioxidants are generally believed to inhibit the development of cardiovascular disease and cancer by neutralizing free radical damage (Meydani 1995) . Therefore, consumption of vitamin E-enriched foods may reduce the incidence of these two diseases. Vitamin E is present in most edible oils extracted from wheat, rice bran, barley, oat, coconut, and palm. The richest sources of tocotrienol specifically are the rice bran, palm, and annatto oils, for which the ratio of tocopherol to tocotrienol is 50:50; 25:75, and 0.1:99.9, respectively (Tan, spacedoc.net). Other natural sources of tocotrienol are rye, amaranth, walnut, hazelnut, poppy, safflower, maize, and the seeds of flax, grape, and pumpkin.
Tocotrienol and tocopherol, which are fat soluble, are structurally similar in that they have a common chromanol ring and a side chain at the C-2 position. But whereas tocopherol has a saturated phytyl tail, tocotrienol possesses an unsaturated isoprenoid side chain (Fig. 1) . Depending on the number and position of methyl substitutions on the chromanol ring, tocotrienol, and tocopherol are further classified into a, b, c, and d isoforms (Fig. 1) .
Tocotrienol derivatives did not attract much attention from researchers until the late 1980s, when their cholesterol-lowering potential (Qureshi et al. 1986 ) and anticancer effects were described (Kato et al. 1985; Sundram et al. 1989) . Evidence now suggests that tocotrienols have potentially greater physiologic functions than tocopherols do (Ahmad et al. 2005; Ong et al. 1993; Yu et al. 1999; Kannappan et al. 2010a; Kannappan et al. 2010b) . For instance, the ability to inhibit the inflammatory transcription factors nuclear factor (NF)-jB and signal transducer and activator of transcription (STAT) 3, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, mammalian DNA polymerases, and certain protein tyrosine kinases is unique to tocotrienols.
In the last few years, much emphasis has been placed on designing drugs that hit a single target (''smart drugs'' or ''magic bullets''). Well-known targeted therapies include celecoxib (which inhibits cyclooxygenase (COX)-2), cetixumab (epidermal growth factor receptor (EGFR)), bortezomib (NF-jB), etanercep (tumor necrosis factor (TNF)), trastuzumab (human epidermal growth factor receptor (HER)-2), imatinib mesylate (breakpoint cluster region (Bcr)-abl), bevacizumab (vascular endothelial growth factor (VEGF)), paclitaxel (tubulin), and camptothecin (topoisomerase). Yet several of these expensive drugs have been found to be ineffective and unsafe. Most diseases, especially cancer, are a result of dysregulation of as many as 500 gene products (Gupta et al. 2010b; Vogelstein and Kinzler 2004) , and inhibition of a single target or signaling pathway is unlikely to prevent or control the disease. Therefore, drugs that modulate multiple targets (multitargeted therapy), formally referred to as ''dirty drugs,'' are needed (Kannappan et al. 2011) . In this review, we examine in detail how tocotrienol modulates various pathways (Table 1 ) and contribute to cancer.
Tocotrienol and signaling pathways

NF-jB and tocotrienol
First discovered in 1986, the transcription factor NF-jB is closely connected to the process of tumorogenesis (Sen and Baltimore 1986) . NF-jB is activated in response to tobacco, stress, dietary agents, obesity, alcohol, infectious agents, irradiation, and other environmental stimuli that account for as much as 95% of all cancers (Gupta et al. 2010a) . It has been linked with the transformation of normal cells and is constitutively active in most tumor cells. Furthermore, NF-jB-regulated gene products have been implicated in cell transformation, proliferation, survival, invasion, angiogenesis, metastasis, and chemoresistance.
We studied the effect of c-tocotrienol on the NF-jB pathway and found that it completely abolished NF-jB activation induced by TNF, phorbol myristate acetate, okadaic acid, lipopolysaccharide, cigarette smoke, interleukin (IL)-1b, and epidermal growth factor (Ahn et al. 2007 ). Park et al. (2010) Suppressed preneoplastic mammary epithelial cell proliferation Sylvester et al. (2002) Exhibited synergism with erlotinib/gefitinib in suppressing cell proliferation Bachawal et al. (2010) Inhibited cell growth irrespective of estrogen receptor status Nesaretnam et al. (1998) Exhibited antiproliferation and induced apoptosis by DNA fragmentation McIntyre et al. (2000a) , McIntyre et al. (2000b) , Comitato et al. (2009) Induced apoptosis in tumor cells through endoplasmic reticulum stress Park et al. (2010) Induced apoptosis through TGF-b/Fas/JNK-signaling pathway Shun et al. (2004) Reduced PI3K/PDK-1/Akt signaling Sylvester et al. (2005) Inhibited cell proliferation and induced apoptosis Shah and Sylvester (2004) , Shah and Sylvester (2005b) , Sylvester and Shah (2005b) , Samant et al. (2010) Induced apoptosis through activation of caspases Shah et al. (2003) , Sylvester and Shah (2005a) Suppressed cell proliferation and down-regulated Bcl-2 and cyclin D1 Hsieh and Wu (2008) Inhibited ER-negative and ER-positive cell proliferation Guthrie et al. (1997) , Nesaretnam et al. (1995) Inhibited proliferation by arresting cell cycle progression Samant et al. (2010) , Wali et al. (2009a) Inhibited tumor cell growth by suppressing HMGR activity Wali et al. (2009b) Induced apoptosis through mitochondria-mediated death pathway Takahashi and Loo (2004) Inhibited proliferation through down-regulation of Id1 protein Reduced cell viability and induced apoptosis via the mitochondrial pathway Pierpaoli et al. 
Induced Bax-and Bid-regulated apoptosis Sakai et al. (2006) Lung Induced apoptosis on accumulation of cells in G1 phase through mutation of ras genes Yano et al. (2005) Suppressed survival and invasion capacity of the tumor cells Kashiwagi et al. (2008) Pancreas Induced apoptosis and autophagy through the mitochondrial death pathway Rickmann et al. (2007) Induced apoptosis and cycle arrest at G1 phase Hussein and Mo (2009) Sensitized to gemcitabine by modulating the inflammatory microenvironment Kunnumakkara et al. (2010) Prostate Inhibited cellular proliferation and accelerated apoptotic events Srivastava and Gupta (2006) Suppressed proliferation and invasion through multiple signaling pathways Yap et al. (2008) Activated caspase-dependent programmed cell death Constantinou et al. (2009) Chemosensitized in the treatment of hormone-refractory cancer Skin Inhibited proliferation and potentiated lovastatin-mediated growth suppression
McAnally et al. (2007) Induced apoptosis by activating pro-caspases and accumulating sub-G1 population Chang et al. (2009) Induced apoptosis, suppressed invasion, sensitized chemotherapeutic drugs Chang et al. (2009) Stomach Induced apoptosis through down-regulation of the Raf/ERK pathway Sun et al. (2008) Induced apoptosis via mitochondria-dependent apoptosis pathway Sun et al. (2009) Inhibited cell migration and invasion through down-regulation of MMP Liu et al. (2010) Genes Nutr (2012) 7:43-52 45
Constitutive NF-jB activation expressed by certain tumor cells was also abrogated by c-tocotrienol. When we investigated the mechanism, we found that tocotrienol blocked TNF-induced phosphorylation and degradation of IjBa by inhibiting IjBa kinase activation, thus leading to the suppression of the phosphorylation and nuclear translocation of p65 (Ahn et al. 2007 ). Yap et al. (2008) investigated the antiproliferative effect of tocotrienol-rich fraction (TRF) on prostate cancer cells and showed that the c-tocotrienolinduced apoptosis was associated with the activation of procaspases and suppression of NF-jB, EGFR, and Id family proteins. The group also found that the c-jun N-terminal kinase-specific inhibitor SP600125 partially reversed the effect of c-tocotrienol. Similar results were observed by Wu et al. (2008) , who investigated the effects of TRF on lipopolysaccharide-induced inflammatory response. TRF dose dependently protected human monocytic (THP-1) cells against lipopolysaccharide-induced cell death through the inhibition of nitric oxide, prostaglandin E2, and proinflammatory cytokines. TRF also blocked lipopolysaccharide induction of inducible nitric oxide synthase, COX-2, and NF-jB expression . Recently, we showed that tocotrienol potentiates the effect of gemcitabine, a standard part of clinical treatment against pancreatic cancer, against human pancreatic cancer cells both in vitro and in vivo. Pancreatic cancers generally respond poorly to chemotherapy, and agents that could sensitize these tumors to treatment need to be identified. In our study, tocotrienol inhibited NF-jB activation and suppressed key cellular regulators, including cyclin D1, c-myc, COX-2, B-cell lymphoma protein 2 (Bcl-2), cellular inhibitor of apoptosis protein, survivin, VEGF, intracellular adhesion molecule-1, and chemokine (C-X-C motif) receptor 4. Furthermore, in an orthotopic nude mouse model of human pancreatic cancer, oral administration of tocotrienol inhibited tumor growth and enhanced the antitumor properties of gemcitabine by inhibiting NF-jB (Kunnumakkara et al. 2010 ).
STAT3 and tocotrienol
STAT3, which was discovered almost 15 years ago as an acute-phase response factor, belongs to one of six members of a family of transcription factors that are linked with inflammation, cellular transformation, survival, proliferation, invasion, angiogenesis, and metastasis of cancer. Like NF-jB, STAT3 is activated by various types of carcinogens, radiation, viruses, growth factors, oncogenes, and inflammatory cytokines and is constitutively active in most tumor cells. STAT3 regulates the expression of genes that mediate proliferation (e.g., c-fos, c-myc, and cyclin D1), suppress apoptosis (e.g., bcl-xL and survivin), invasion (e.g., matrix metalloproteinase-2), and promote angiogenesis (e.g., the VEGF gene). Activation of STAT3 has also been associated with chemoresistance and radioresistance. STAT3 mediates these effects through its collaboration with other transcription factors, including NF-jB, hypoxiainducible factor (HIF)-1, and peroxisome proliferatoractivated receptor (PPAR)-c. Thus, inhibitors of STAT3 activation might be used for cancer prevention and therapy. Small peptides, oligonucleotides, and small molecules have been identified as potential STAT-3 inhibitors, including synthetic molecules (e.g., AG 490, decoy peptides, and oligonucleotides) and plant polyphenols (e.g., curcumin, resveratrol, flavopiridol, indirubin, magnolol, piceatannol, parthenolide, epigallocatechin gallate, and cucurbitacin).
In our laboratory, we investigated whether c-tocotrienol can modulate the STAT3 cell signaling pathway and discovered that c-tocotrienol, but not c-tocopherol, inhibited constitutive activation of STAT3 in multiple myeloma cells (Kannappan et al. 2010b) (Fig. 2) . Tocotrienol inhibited the activation of Src kinase, Janus kinase (JAK) 1, and Komiyama et al. (1989) Inhibited tumor promotion in human lymphoblastoid cells Goh et al. (1994) Inhibited proliferation and tube formation and minimized angiogenesis Birringer et al. (2002) Blocked STAT3 pathway and sensitized to chemotherapeutic agents Kannappan et al. (2010b) CHOP C/EBP homologous protein, DR death receptor, ER estrogen receptor, ERK extracellular signal-regulated kinase, HIF-1 hypoxiainducible factor-1, HMGR 3-hydroxy-3-methyl-glutaryl coenzyme A reductase, Id1 inhibitor of differentiation, JNK c-Jun N-terminal kinase, MMP matrix metalloproteinase, ROS reactive oxygen species, TGF transforming growth factor JAK2, which are believed to be the regulators of STAT3. We further found that c-tocotrienol-induced expression of the tyrosine phosphatase SHP-1 and that gene silencing of SHP-1 with small interfering RNA reversed the ability of tocotrienol to inhibit STAT3 activation; this result suggested that SHP-1 plays a vital role in the action of c-tocotrienol. Tocotrienol down-modulated the activation of STAT3 and induced SHP-1 in vivo as well. Eventually, c-tocotrienol down-regulated the expression of STAT3-regulated antiapoptotic, proliferative, and angiogenic gene products (Kannappan et al. 2010b ). Bachawal et al. (2010) investigated the effect of combined treatment of c-tocotrienol and a tyrosine kinase inhibitor (erlotinib or gefitinib) on STAT and Akt signaling in murine mammary tumor cells. In their study 3 lM c-tocotrienol with 0.25 lM erlotinib or 0.5 lM gefitinib significantly inhibited anchorage-independent cell growth and reduced levels of cyclin D1 and phosphorylated (i.e., active) Pdk-1, Akt, Stat3, and Stat5. Those researchers concluded that treatment with c-tocotrienol plus erlotinib or gefitinib prevents ErbB receptor heterodimer cooperation and inhibits epidermal growth factor-dependent Fig. 2 Tocotrienol targets multiple cell signaling pathways. Modern mono-targeted therapies include celecoxib, avastin, erbitux, enbrel, herceptin, gleevec, and avastin (inhibits COX2, EGFR, TNF, HER2, bcr-abl and VEGF, respectively) and also inhibits other targets including transcription factors, enzymes, growth factors and its receptors, kinases, and anti-apoptotic proteins. Note: Celecoxib, a non-steroidal anti-inflammatory drug that selectively inhibit COX-2; avastin (bevacizumab), monoclonal antibody against VEGF; Herceptin (Trastuzumab), humanized monoclonal antibody against HER-2; Gleevac (imatinib), a multiple tyrosine kinase inhibitor. AGP, human alpha1-acid glycoprotein; AP-1, activating protein-1; Bcl-2, B-cell lymphoma protein 2; COX-2, cyclooxygenase; DNA poly, DNA polymerase; DR, death receptor; EGFR, EGF-receptor; ER, estrogen receptor; ERK, extracellular receptor kinase; GST, glutathione-Stransferase; HER-2, human epidermal growth factor receptor-2; HIF1a, hypoxia-inducible factor-1 alpha; IAP, inhibitory apoptosis protein; ICAM-1, intracellular adhesion molecule-1; IL, interleukin; iNOS, inducible nitric oxide synthase; JAK, janus kinase; NF-jB, nuclear factor kappa B; MMP, Matrix metalloproteinase; PKC, protein kinase C, STAT, signal transducers, and activators of transcription; VCAM-1, vascular cell adhesion molecule-1; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor; IFN-c, interferon gamma; PF-4, Platelet factor 4; 12-LOX, 12-lipoxygenase; eNOS, endothelial nitric oxide synthase; GGT, gamma-glutamyl transpeptidase; GSTP-1, glutathione-S-transferase pi; HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase; hTERT, human telomerase reverse transcriptase; NQO1, NAD(P)H dehydrogenase, quinone1; PLA-2, phospholipase A2; TRAF-1, TNF receptor-associated factor-1; XIAP, X-linked inhibitor of apoptosis protein; c-FLIP, cellular FLICE inhibitory protein, CDK, cyclin-dependent kinase; IKK, IjB kinase; Pdk-1, phosphoinositide-dependent kinase-1; PI3K, phosphoinositide 3-kinase; C/EBP-a, CCAAT/enhancer-binding protein alpha; PPAR-c, peroxisome proliferator-activated receptor gamma; PGE-2, prostaglandin E2; TX-B2, thromboxane B2 Genes Nutr (2012) 7:43-52 47 mitogenic signaling in anchorage-independent murine mammary tumor cells (Bachawal et al. 2010 ).
Death receptors and tocotrienol
Recent innovative strategy in cancer therapy is the induction of apoptosis in tumor cells through agents that induces death receptors (DRs). The best characterized DRs are CD95 (Fas/Apo-1), TNF receptor, and TNF-related apoptosis-inducing ligand (TRAIL) receptors. TRAIL is emerging as the most promising agent for cancer therapy because it induces apoptosis in a variety of tumor and transformed cells without being toxic to normal cells. In 1995, the ligand itself was discovered on the basis of its sequence homology to TNF and Fas ligand. TRAIL interacts with at least six proteins, of which DR4 and DR5 recruit the adaptor molecule FADD and either the FLICE caspase or caspase-8. Activation of caspase-8 leads directly to the activation of caspase-3 and subsequently apoptosis; this is the extrinsic apoptosis pathway. Cross-talk exists between this extrinsic pathway and the mitochondriadependent intrinsic apoptosis pathway. Activated caspase-8 cleaves Bid, which then translocates to the mitochondria to induce cytochrome c release, which in turn leads to sequential activation of caspase-9 and caspase-3. Although TRAIL can induce apoptosis in most cancer cells, the emergence of resistance to TRAIL limits its utility as a therapeutic agent. Thus, agents that up-regulate DRs have the potential to sensitize tumors to TRAIL. We investigated whether tocotrienol can promote TRAIL-induced apoptosis in colon cancer cells and found that it can sensitize human colon cancer cells to TRAIL (Kannappan et al. 2010a ). We also discovered that tocotrienol induced DR expression in a non-cell-type-specific fashion that is mediated through reactive oxygen species/ extracellular signal-regulated kinase/p53. Similarly, Park et al. (2010) observed that tocotrienol induces apoptosis in breast cancer cell lines via an endoplasmic reticulum stressdependent increase in extrinsic death receptor signaling. However, they found that DR5 induction by tocotrienol was transcriptionally regulated by C/EBP homologous protein. These researchers concluded that up-regulation of DR5 by c-tocotrienol treatment is dependent on the activation of c-jun N-terminal kinase and p38 mitogen-activated protein kinase and that the activation is mediated by endoplasmic reticulum stress (Park et al. 2010 ).
Apoptosis and tocotrienol
Every cell has a finite life span. Cell death is due to passive necrotic processes or to the active process of apoptosis. During apoptosis, the most common mechanism by which the body eliminates damaged or unneeded cells, the cells die without local inflammation from leakage of cell contents (Raff 1998) . Morphologic changes, such as cell shrinkage, condensation, fragmentation of the nucleus and bubbling of the plasma membrane (''blebbing''), and chromatin condensation and nucleosomal fragmentation are characteristics of cells undergoing apoptosis (Heermeier et al. 1996; Hockenbery et al. 1990; Nass et al. 1996) . Cancer cells can be eliminated from the body through the apoptosis mechanism (Kerr et al. 1972) . Sundram et al. (1989) were the first to demonstrate that palm oil possesses anticancer properties in female SpragueDawley rats. Yu et al. (1999) reported that all tocotrienol derivatives and RRR-c-tocopherol induce apoptosis in MDA-MB-435 human breast cancer cell lines. However, accumulating evidence suggests that tocopherols have little or no apoptotic activity (Kimmick et al. 1997; Kline et al. 2004; Aggarwal et al. 2010; Neuzil et al. 2002; Schneider 2005) . How tocotrienol triggers this natural process of cell death has been investigated extensively. Studies of the intracellular mechanisms mediating tocotrienol-induced apoptosis in neoplastic mammary epithelial cells revealed that c-tocotrienol induced caspases-8 and -3 but not caspase-9 activation (Shah et al. 2003; Shah and Sylvester 2004) . Caspase-8 processing and activation are associated with DR-mediated apoptotic signaling, whereas caspase-9 activation and processing are associated with mitochondrial stress-mediated apoptotic signaling. Takahashi and Loo (2004) observed disrupted mitochondria in c-tocotrienoltreated human breast cancer cells, collapsed mitochondrial membrane potential, and cytochrome c release from mitochondria, but the level of Bcl-2 protein and the induction of caspase-9 activation were unchanged in these cells. In a study of human colon carcinoma cells, tocotrienol altered the ratio of Bax to Bcl-2, which induced mitochondrial disruption, cytochrome c release, and caspase-9 activation (Agarwal et al. 2004) . Taken together, these results demonstrate that tocotrienol mediates its apoptotic effect through the activation of different intracellular signaling mechanisms in different types of cancer cells. Many other investigators have also reported that tocotrienol exhibits anticancer properties by inducing apoptosis (Shah et al. 2003; Shah and Sylvester 2004; Takahashi and Loo 2004; Agarwal et al. 2004; McIntyre et al. 2000a McIntyre et al. , 2000b Osakada et al. 2004; Sakai et al. 2004; Shun et al. 2004 ).
Nrf2 and tocotrienol
Nuclear factor (erythroid derived 2)-like 2 (Nrf2, also known as NFE2L2) plays a critical role in protecting cells against oxidative stress. Nrf2 is sequestered in cytoplasm by the cytoskeletal protein Keapl. Under stress conditions, when electrophiles or reactive oxygen species (or both) cause dissociation of Nrf2 from Keap1, the former is translocated to the nucleus, leading to activation of the phase I and II enzymes responsible for the inactivation and removal of mutagenic and carcinogenic factors. Induction of phase II enzymes confers protection against insult by reactive metabolites of carcinogens or by reactive oxygen species. Nrf is a potential target for cancer chemoprevention because it can induce these enzymes, and agents that induce Nrf2 are under investigation. Hsieh et al. (2010) found that tocotrienol treatment induced Nrf2 expression, as indicated by a corresponding decrease in Keap1 levels in estrogen receptor-negative MDA-MB-231 cells but not in estrogen receptor-positive MCF-7 cells.
HIF-1 and tocotrienol
Hypoxia-inducible factors (HIFs) are principal regulators of hypoxic adaptation. They regulate gene expression involved in glycolysis, erythropoiesis, angiogenesis, proliferation, and stem cell function under low-oxygen conditions. Evidence accumulated in recent years suggests an additional important regulatory role for HIFs in inflammation: HIF-1a promotes survival under oxygen-deprived conditions and mediates blood vessel extravasation by modulating b 2 -integrin expression. The method by which hypoxia and HIFs control properties of tumor-associated macrophages and their relationship to tumor formation and progression have been established.
HIF-1a, its downstream target VEGF, and other angiogenic factors such as IL-8 and COX-2 play critical roles in neovascularization. Shibata et al. (2008a) investigated whether the inhibitory effect of tocotrienol on tumor angiogenesis is via regulation of these angiogenic factors. They found that d-tocotrienol suppressed hypoxia-induced VEGF and IL-8 expression in DLD-1 cells at both the mRNA and the protein levels and that d-tocotrienol reduced HIF-1a protein expression or increased HIF-1a degradation. Similarly, Bi et al. (2010) showed that c-tocotrienol decreased the expression of HIF-1a protein and the paracrine secretion of VEGF under both normoxic and hypoxic conditions in the human gastric adenocarcinoma SGC-7901 cell line.
Growth factor receptor kinases and tocotrienol
A variety of growth factor receptor kinases have been discovered and many of them are linked to tumorigenesis. For example, Src tyrosine kinases are involved in different signal transduction pathways in cells. The corresponding genes participate in such vital processes as growth, differentiation, adhesion, and transcription. Specific structural changes confer oncogenic properties to the Src protein (Guarino 2010) . We and other research groups have found that tocotrienol inhibits Src kinase activity and induces apoptosis in various cell types (Kannappan et al. 2010b; Sen et al. 2000; Kashiwagi et al. 2009 ).
JAK plays an essential and non-redundant role in promoting biologic responses to multiple major cytokine receptor families (Rodig et al. 1998) , and it has been shown to mediate IL-6-induced STAT3 activation (Ueda et al. 2002) . Thus, inhibition of JAK activation by IL-6 should lead to down-regulation of STAT3 activation. We investigated whether tocotrienol can modulate the effect of IL-6-induced STAT3 and found that tocotrienol inhibited STAT3 activation through inhibition of JAK activation in U266 multiple myeloma cells and that it also inhibited IL-6-induced STAT3 activation in MM.1 s cells (Kannappan et al. 2010b) .
Phosphatidylinositol 3-kinase (PI3K) is frequently mutated in cancer cells, and many of these mutations lead to aggressive activation of the kinase. Dysregulation of PI3K activity contributes significantly to cell growth, survival, motility, and metabolism (Ikenoue et al. 2005; Mizoguchi et al. 2004; Samuels and Velculescu 2004) . A number of PI3K pathway inhibitors have been developed and are being evaluated in preclinical studies and early clinical trials (Courtney et al. 2010) . Tocotrienol has been shown to inhibit PI3K/Pl3K-dependent kinase 1 (Pdk-1)/Akt signaling in a phosphatase and tensin homologue deleted from chromosome 10 (PTEN) and in protein phosphatase type 2A independent manner in neoplastic mammary epithelial cells (Sylvester et al. 2005; Shah and Sylvester 2005a) . Samant and Sylvester (2006) found that the effect of tocotrienol on PI3K/Pdk-1/Akt signaling is mediated through the suppression of ErbB3-receptor tyrosine phosphorylation in neoplastic mammary epithelial cells. Finally, Shibata et al. (2008b) investigated the effect of tocotrienol on DLD-1-CM-induced-PI3K/Pdk-1/Akt activation in human umbilical vein endothelial cells (HUVEC). They found that tocotrienol reversed the activation of PDK, Akt, and PTEN as well as their respective downstream gene products, endothelialinducible nitric oxide synthase, glycogen synthase kinase 3 a/b, and extracellular receptor kinase (ERK) 1/2.
Angiogenic pathways and tocotrienol
Angiogenesis is a process of forming new blood vessels from an existing vascular bed. It normally involves a series of steps, including endothelial cell activation, breakdown of the basement membrane, migration, proliferation, and tube formation of the endothelial cell (Folkman and Shing 1992) . Modulation of angiogenesis is now a recognized strategy for preventing various angiogenesis-mediated disorders, including solid tumors. Miyazawa and colleagues investigated whether tocotrienol can modulate VEGF-stimulated tube formation in HUVEC. They found that tocotrienol inhibited tube formation and concluded that it might be useful as a therapeutic dietary supplement to minimize tumor angiogenesis (Inokuchi et al. 2003; Miyazawa et al. 2004a; Miyazawa et al. 2004b ). Later, this research group reported that tocotrienol also inhibited angiogenesis in in vivo animal models, a dorsal air sac model, and a chick chorioallantoic membrane model (Miyazawa et al. 2009 ). They found that in the dorsal air sac model, increased neovascularization in mice that had been implanted with human colon carcinoma DLD-1 cells was suppressed by daily dietary supplementation of 10 mg of tocotrienol-rich oil (equivalent to 4.4 mg of pure tocotrienol). In the chorioallantoic membrane model, they found that tocotrienol treatment (500-1000 lg/egg) inhibited the angiogenic response (Miyazawa et al. 2009 ).
Because VEGF receptor-2 is the key protein in growth factor signal transduction in endothelial cells (Ferrara et al. 2003) , regulation of VEGFR-2 activation is a potential molecular target of antiangiogenic compounds (Schlaeppi and Wood 1999) . Several researchers have investigated whether the antiangiogenic activity of tocotrienol works via the modulation of VEGF-induced VEGFR-2 phosphorylation. In HUVEC, tocotrienol inhibited the VEGFinduced VEGFR-2 phosphorylation, whereas tocopherol had no effect (Miyazawa et al. 2009; Shibata et al. 2009 
Conclusion
Whereas more than 25,000 studies on tocopherol have been carried out, relatively little is known about tocotrienol. This review suggests that tocotrienol affects numerous pathways linked with tumorigenesis and thus has potential in both the prevention and the treatment of cancer. Additional studies are required to determine the specific intracellular sites of action that tocotrienol and derivatives target in order to fully understand the mechanisms of action mediating their anticancer and apoptotic effects. In addition, the potential value of these compounds as chemotherapeutic agents in the prevention and treatment of various cancers needs to be clarified.
